Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Novavax Inc (NVAX) Price & Performance

iShares MSCI Japan ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Novavax Inc — how do they compare? iShares MSCI Japan ETF trades at $97.72, while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

EWJNVAX
Sector
Broad Market / FactorHealth
52-Week High
$96.97$11.19
52-Week Low
$77.93$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ (iShares MSCI Japan ETF) trades at $98.12, up 2.16% with strong bullish technical signals from moving averages. The ETF benefits from recent U.S.-Japan currency intervention supporting the yen, while facing headwinds from Japan's inflation dynamics and export pressures. Technical indicators show overbought conditions with RSI at 84.79, suggesting potential near-term consolidation.

Outlook remains cautiously optimistic as Japanese equities respond to policy support, though currency volatility and economic uncertainty present risks. The fund's exposure to Japan's export sector faces challenges from yen strength, while domestic stimulus measures could provide upside potential for consumer-focused holdings.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX